share_log

Biora Therapeutics | 424B5: Prospectus

Biora Therapeutics | 424B5: Prospectus

Biora Therapeutics | 424B5：募资说明书
SEC announcement ·  04/02 16:45
Moomoo AI 已提取核心信息
Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends information from the original prospectus dated August 6, 2021, and the subsequent supplement dated November 6, 2022. The supplement pertains to the offering and sale of 1,300,250 shares of common stock, including shares issuable upon the exercise of warrants for up to 800,000 shares. The exercise price of these warrants was adjusted from $0.3288 to $8.22 following a reverse stock split in January 2023. On March 31, 2024, Biora Therapeutics entered into a Warrant Amendment Agreement with an institutional investor to further amend these warrants. The amendments include a reduction in the exercise price to $1.10 per share, a condition that the warrants will not be exercisable until stockholder approval is received, and an extension of the expiration date to five years post-approval. The company's common stock is traded on the Nasdaq Global Market under the symbol 'BIOR', with a last reported sale price of $1.10 per share as of March 28, 2024.
Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends information from the original prospectus dated August 6, 2021, and the subsequent supplement dated November 6, 2022. The supplement pertains to the offering and sale of 1,300,250 shares of common stock, including shares issuable upon the exercise of warrants for up to 800,000 shares. The exercise price of these warrants was adjusted from $0.3288 to $8.22 following a reverse stock split in January 2023. On March 31, 2024, Biora Therapeutics entered into a Warrant Amendment Agreement with an institutional investor to further amend these warrants. The amendments include a reduction in the exercise price to $1.10 per share, a condition that the warrants will not be exercisable until stockholder approval is received, and an extension of the expiration date to five years post-approval. The company's common stock is traded on the Nasdaq Global Market under the symbol 'BIOR', with a last reported sale price of $1.10 per share as of March 28, 2024.
Biora Therapeutics, Inc.已于2024年4月2日提交了招股说明书补充文件，其中更新和修订了2021年8月6日的原始招股说明书以及随后于2022年11月6日发布的补充说明书中的信息。该补编涉及1300,250股普通股的发行和出售，包括在行使不超过80万股的认股权证时可发行的股票。在2023年1月进行反向股票拆分后，这些认股权证的行使价从0.3288美元调整至8.22美元。2024年3月31日，Biora Therapeutics与一家机构投资者签订了认股权证修正协议，以进一步修改这些认股权证。修正案包括将行使价降至每股1.10美元，条件是认股权证在获得股东批准之前不得行使，以及将到期日延长至批准后的五年。该公司的普通股在纳斯达克全球市场上市，股票代码为 “BIOR”，截至2024年3月28日，最新公布的销售价格为每股1.10美元。
Biora Therapeutics, Inc.已于2024年4月2日提交了招股说明书补充文件，其中更新和修订了2021年8月6日的原始招股说明书以及随后于2022年11月6日发布的补充说明书中的信息。该补编涉及1300,250股普通股的发行和出售，包括在行使不超过80万股的认股权证时可发行的股票。在2023年1月进行反向股票拆分后，这些认股权证的行使价从0.3288美元调整至8.22美元。2024年3月31日，Biora Therapeutics与一家机构投资者签订了认股权证修正协议，以进一步修改这些认股权证。修正案包括将行使价降至每股1.10美元，条件是认股权证在获得股东批准之前不得行使，以及将到期日延长至批准后的五年。该公司的普通股在纳斯达克全球市场上市，股票代码为 “BIOR”，截至2024年3月28日，最新公布的销售价格为每股1.10美元。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息